Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial | Zendy

Mark M. Smits | Zendy; Lennart Tonneijck | Zendy; Marcel H.A. Muskiet | Zendy; Mark H.H. Kramer | Zendy; Indra C. Pieters-van den Bos | Zendy; Karuna E.W. Vendrik | Zendy; Trynke Hoekstra | Zendy; Marco J. Bruno | Zendy; Michaëla Diamant | Zendy; Daniël H. van Raalte | Zendy; Djuna L. Cahen | Zendy

Open Access

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial

Author(s) -

Mark M. Smits,

Lennart Tonneijck,

Marcel H.A. Muskiet,

Mark H.H. Kramer,

Indra C. Pieters-van den Bos,

Karuna E.W. Vendrik,

Trynke Hoekstra,

Marco J. Bruno,

Michaëla Diamant,

Daniël H. van Raalte,

Djuna L. Cahen

Publication year - 2016

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc16-0836

Subject(s) - medicine , liraglutide , sitagliptin , placebo , type 2 diabetes , overweight , diabetes mellitus , randomized controlled trial , sitagliptin phosphate , endocrinology , obesity , alternative medicine , pathology

To assess the mechanistic effects of the glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide and the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin on (exocrine) pancreatic physiology and morphology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research